Switching to faricimab allowed for significantly extending the recurrence-free IVI interval and decreasing the proportion of exudative patients in this cohort. Significant extension was found in a wide range of patients, including those without a loading phase. Further controlled prospective studies are needed to assess the value of a loading phase when switching to faricimab. Safety outcomes were consistent with prior studies.
Posnic et al. (Tue,) studied this question.